93 related articles for article (PubMed ID: 18923384)
1. An in vitro model of light chain deposition disease.
Keeling J; Herrera GA
Kidney Int; 2009 Mar; 75(6):634-45. PubMed ID: 18923384
[TBL] [Abstract][Full Text] [Related]
2. Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis.
Herrera GA; Turbat-Herrera EA; Teng J
Nephron; 2016; 132(2):119-36. PubMed ID: 26794829
[TBL] [Abstract][Full Text] [Related]
3. Glomerulopathic light chain-mesangial cell interactions modulate in vitro extracellular matrix remodeling and reproduce mesangiopathic findings documented in vivo.
Herrera GA; Russell WJ; Isaac J; Turbat-Herrera EA; Tagouri YM; Sanders PW; Picken MM; Dempsey S
Ultrastruct Pathol; 1999; 23(2):107-26. PubMed ID: 10369104
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta.
Zhu L; Herrera GA; Murphy-Ullrich JE; Huang ZQ; Sanders PW
Am J Pathol; 1995 Aug; 147(2):375-85. PubMed ID: 7639331
[TBL] [Abstract][Full Text] [Related]
5. Integrated expression of glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light chain-related renal diseases.
Turbat-Herrera EA; Isaac J; Sanders PW; Truong LD; Herrera GA
Mod Pathol; 1997 May; 10(5):485-95. PubMed ID: 9160315
[TBL] [Abstract][Full Text] [Related]
6. Insights into mechanisms responsible for mesangial alterations associated with fibrogenic glomerulopathic light chains.
Teng J; Zhang PL; Russell WJ; Zheng LP; Jones ML; Herrera GA
Nephron Physiol; 2003; 94(2):p28-38. PubMed ID: 12845220
[TBL] [Abstract][Full Text] [Related]
7. AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells.
Keeling J; Teng J; Herrera GA
Lab Invest; 2004 Oct; 84(10):1322-38. PubMed ID: 15286662
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic plasticity of mesenchymal stem cells is crucial for mesangial repair in a model of immunoglobulin light chain-associated mesangial damage.
Herrera GA; Teng J; Zeng C; Xu H; Liang M; Alexander JS; Liu B; Boyer C; Turbat-Herrera EA
Ultrastruct Pathol; 2018; 42(3):262-288. PubMed ID: 29668344
[TBL] [Abstract][Full Text] [Related]
9. Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy?
McLennan SV; Kelly DJ; Schache M; Waltham M; Dy V; Langham RG; Yue DK; Gilbert RE
Kidney Int; 2007 Aug; 72(4):481-8. PubMed ID: 17554258
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal light chain--mesangial cell interactions: early signaling events and subsequent pathologic effects.
Russell WJ; Cardelli J; Harris E; Baier RJ; Herrera GA
Lab Invest; 2001 May; 81(5):689-703. PubMed ID: 11351041
[TBL] [Abstract][Full Text] [Related]
11. Glomerular expression of platelet-derived growth factor (PDGF)-A, -B chain and PDGF receptor-alpha, -beta in human diabetic nephropathy.
Uehara G; Suzuki D; Toyoda M; Umezono T; Sakai H
Clin Exp Nephrol; 2004 Mar; 8(1):36-42. PubMed ID: 15067514
[TBL] [Abstract][Full Text] [Related]
12. The role of megsin, a serine protease inhibitor, in diabetic mesangial matrix accumulation.
Ohtomo S; Nangaku M; Izuhara Y; Yamada N; Dan T; Mori T; Ito S; van Ypersele de Strihou C; Miyata T
Kidney Int; 2008 Sep; 74(6):768-74. PubMed ID: 18580857
[TBL] [Abstract][Full Text] [Related]
13. Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats.
Okada M; Takemura T; Yanagida H; Yoshioka K
Kidney Int; 2002 Jan; 61(1):113-24. PubMed ID: 11786091
[TBL] [Abstract][Full Text] [Related]
14. Morphologic heterogeneity of renal light-chain deposition disease.
Gokden N; Barlogie B; Liapis H
Ultrastruct Pathol; 2008; 32(1):17-24. PubMed ID: 18300034
[TBL] [Abstract][Full Text] [Related]
15. Purple corn anthocyanins dampened high-glucose-induced mesangial fibrosis and inflammation: possible renoprotective role in diabetic nephropathy.
Li J; Lim SS; Lee JY; Kim JK; Kang SW; Kim JL; Kang YH
J Nutr Biochem; 2012 Apr; 23(4):320-31. PubMed ID: 21543205
[TBL] [Abstract][Full Text] [Related]
16. High glucose concentration induces the overexpression of transforming growth factor-beta through the activation of a platelet-derived growth factor loop in human mesangial cells.
Di Paolo S; Gesualdo L; Ranieri E; Grandaliano G; Schena FP
Am J Pathol; 1996 Dec; 149(6):2095-106. PubMed ID: 8952542
[TBL] [Abstract][Full Text] [Related]
17. Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease.
Herrera GA; Teng J; Turbat-Herrera EA; Zeng C; Del Pozo-Yauner L
Kidney Int Rep; 2020 Nov; 5(11):1870-1893. PubMed ID: 33163710
[TBL] [Abstract][Full Text] [Related]
18. In vitro modulation of AL-amyloid formation by human mesangial cells exposed to amyloidogenic light chains.
Isaac J; Kerby JD; Russell WJ; Dempsey SC; Sanders PW; Herrera GA
Amyloid; 1998 Dec; 5(4):238-46. PubMed ID: 10036581
[TBL] [Abstract][Full Text] [Related]
19. The combination of thrombotic microangiopathy and nodular sclerosis in light chain deposition disease.
Kanjanabuch T; Bunruang R; Srisawat N; Lewsuwan S; Kittikovit V; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S248-52. PubMed ID: 17044479
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Mohan M; Buros A; Mathur P; Gokden N; Singh M; Susanibar S; Jo Kamimoto J; Hoque S; Radhakrishnan M; Matin A; Davis C; Grazziutti M; Thanendrarajan S; van Rhee F; Zangari M; Davies F; Morgan G; Epstein J; Barlogie B; Schinke C
Am J Hematol; 2017 Aug; 92(8):739-745. PubMed ID: 28383130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
